Kumar Amit, Khurana Ujjawal, Chowdhary Rashmi, Halder Ajay, Kapoor Neelkamal
All India Institute of Medical Sciences, Department of Pathology and Lab Medicine, Bhopal, India.
All India Institute of Medical Sciences, Department of Biochemistry, Bhopal, India.
Turk J Obstet Gynecol. 2024 Mar 4;21(1):43-50. doi: 10.4274/tjod.galenos.2024.38265.
MCAM-1 (CD146) is an endothelial cell adhesion molecule belonging to the immunoglobulin superfamily. Recent studies have identified CD146 expression as a critical marker for tumor progression, migration, and metastasis in various malignancies. This study aimed to evaluate CD146 immunohistochemical expression in various gynecological cancers.
This study was conducted in a tertiary medical center in central India. A total of 49 gynecological cancer cases and 16 site-matched controls were included. The cases comprised 27 cervical, 10 endometrial, 10 ovarian, and two miscellaneous cancers. CD146 immunohistochemistry was performed and assessed for immunoreactivity score (IRS), microvascular density (MVD), and microvascular caliber (MVC). An IRS of 5 or more was considered CD146 positive.
The p-values for CD146 positivity for cases vs. control were 0.0531, 0.0580, and 0.007 for cervical, endometrial, and ovarian sites, respectively. The mean MVD was found to be significantly higher in cases compared with benign tissues (p-value <0.00001), and the mean MVC of cases was found to be smaller when compared with the controls (p-value <0.0001).
MVD by CD146 was found to be higher in gynecological malignancies, highlighting its role in cancer neo-angiogenesis and its potential therapeutic role. CD146 epithelial expression was also significantly higher in ovarian cancers. Further studies with a larger sample size are required to confirm that this protein may be a potential theognostic target in gynecological cancers.
MCAM-1（CD146）是一种属于免疫球蛋白超家族的内皮细胞黏附分子。最近的研究已将CD146表达确定为各种恶性肿瘤中肿瘤进展、迁移和转移的关键标志物。本研究旨在评估CD146在各种妇科癌症中的免疫组化表达。
本研究在印度中部的一家三级医疗中心进行。共纳入49例妇科癌症病例和16例部位匹配的对照。病例包括27例宫颈癌、10例子宫内膜癌、10例卵巢癌和2例其他癌症。进行CD146免疫组化检测，并评估免疫反应性评分（IRS）、微血管密度（MVD）和微血管管径（MVC）。IRS为5或更高被认为是CD146阳性。
宫颈癌、子宫内膜癌和卵巢癌病例与对照的CD146阳性p值分别为0.0531、0.0580和0.007。发现病例的平均MVD显著高于良性组织（p值<0.00001），且病例的平均MVC与对照相比更小（p值<0.0001）。
发现CD146的MVD在妇科恶性肿瘤中更高，突出了其在癌症新生血管形成中的作用及其潜在的治疗作用。CD146上皮表达在卵巢癌中也显著更高。需要更大样本量的进一步研究来证实这种蛋白可能是妇科癌症中潜在的诊断靶点。
